Denosumab belongs to a class of drugs known as monoclonal antibodies. Specifically, this drug works as a RANKL inhibitor. By inhibiting RANKL, denosumab achieves its effect by inhibiting the activation of osteoclasts, and its osteoclasts that are responsible for the breakdown of bone.In essence, denosumab prevents bone destruction. This is why it's used to treat conditions such as osteoporosis and act as a prophylaxis in patients who are at high risk of suffering a fracture, such as post-menopausal women. Denosumab has also proven effective in patients who are receiving chemotherapy, as the latter is often responsible for weakening the strength of bones.